Clinical Comparison: Effectiveness, Dosing, Side Effects Effectiveness of tirzepatide: functioning as a dual GIP and GLP-1 receptor agonist, tirzepatide has demonstrated remarkable effectiveness in clinical studies, surpassing both semaglutide and placebo in terms of weight loss and glycemic control
Meaningful weight loss typically begins at 5mg and becomes more pronounced at higher doses
Continuous glucose monitor data from patients on microdosing protocols shows improved time-in-range metrics even without significant weight loss
When you activate all of them simultaneously, the ripple effects are enormous
While these mechanisms can be helpful for diabetes control and weight loss, they can also cause side effects
JAMA Network Several complementary analysesincluding the largest direct comparison of GLP-1 RAs vs metformin as initial therapysuggest GLP-1 drugs may reduce overall and Alzheimers-type dementias more than metformin in people with type 2 diabetes